Will Today's KOL Event Move VXRT Higher?

VXRT shares are now up almost 100% since its 5/26/21 announcement that it was providing a knowledge leader (KOL) event on 5/3/21 at noon (ET) about the importance of a T cell response (i.e. the type of response VXRT saw in their Phase 1 Covid vaccine trial results) to a vaccine's effectiveness, to provide updated comparative T cell response data with other vaccines and new antibody data*. The company also announced last week, that its Chief Scientific Officer will present at the World Vaccine Congress on May 5 at 5PM ET. Until the April 26 announcement, the stock was on a downward trend, with a market cap even after last week's big move under $1.3 billion. The market was disappointed by the initial data readout in early February from VXRTs Phase 1 readout, which reported that neutralizing antibodies were not generated by the oral Covid vaccine candidate. The stock is heavily shorted, with over 20% short interest. The announcement last week of today's KOL event and additional data, might have spurred a short squeeze that magnified the move up based on the 5/26/21 and (to a lesser extent in our view) the 5/29/21 announcement.

Is there more room for this stock to run up further? Given the current enterprise value, there would be plenty of room for growth if VXRT has a COVID vaccine that could take significant market share in countries with combined market size in the $100s millions, either in an initial vaccination or in future boosters. Join BPIQ now, and read our forum post with bull and bear comments about VXRT's vaccine and our speculation about what might happen to the stock after this week's events. Just go to our home page at BPIQ.com and follow the free trial (no credit card) links. Plus, get more info on VXRT on our pipeline page with IQ cards for each asset at BPIQ.com.

Finally, you can also check out our free blog post with helpful chart of investible small and mid-cap covid vaccine companies here: https://bit.ly/3tRMEJ6

https://bit.ly/3ez2mCs